As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Ranibizumab port delivery system for treating wet age-related macular degeneration. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early October 2022. These timings are based on a request from the company to reschedule the initial date set by NICE.